News Release

Chromos expands its Board of Directors

For Immediate Release: February 19, 2002

BURNABY, BC, Canada — Chromos Molecular Systems Inc. ("CHROMOS"; TSE: CHR) announced today the election of Imre Kovesdi, PhD, to its Board of Directors. Dr. Kovesdi is Vice-President and Chief Scientific Officer (CSO) of GenVec Inc., a public biotech company developing and commercializing gene-based products that produce site-specific proteins. At GenVec, he focuses on scientific strategy development in the areas of therapeutic gene selection, functional genomics and vaccines.

" We are very pleased to have attracted Dr. Kovesdi at this important time in Chromos' development," stated Darrell Elliott, Chromos' Chairman of the Board. His expertise and experience in the development and manufacturing of gene-based medicines will provide great value to Chromos as the Company begins its transition into product development.

Dr. Kovesdi has been with GenVec since its inception in 1993. He served in several capacities before becoming CSO, and was responsible for establishing and directing the Company's research, development and manufacturing laboratories. A major contributor to GenVec's intellectual property portfolio, he has managed the integration of the Company's scientific achievements with its business objectives.

Prior to joining GenVec, Dr. Kovesdi led projects in developing gene expression systems and therapeutic gene design at the Medical Research Division of the New York-based American Cyanamid Company. Dr. Kovesdi holds a Ph.D. in molecular biology and is the author of over one hundred peer-reviewed publications. Dr. Kovesdi serves on the boards of a number of biotechnology and information technology companies.

This election brings the number of directors of Chromos' board to eight.

About Chromos

Chromos Molecular Systems Inc. is a public, Canadian-based biotechnology company leading the development of innovative therapies using a proprietary gene delivery and expression system for the production of therapeutic proteins and cell-mediated gene therapies.